At 80 weeks, participants on 4mg of retatrutide lost an average of 17.6% of their body weight, compared with 23.7% on 9mg, 25.0% on 12mg and 3.9% on placebo, the study results revealed
Month 6 and beyond : After achieving at least 10% body weight loss, your provider team will help you decide whether to maintain your current dose, adjust it, or transition to a maintenance phase
Circulating mitochondrial DAMPs cause inflammatory responses to injury
Blood glucose levels should be monitored, and the reduction of existing blood glucose-lowering drugs should be considered
Overall, BPC-157 is valued for its regenerative capabilities, offering potential benefits for injury recovery, gastrointestinal health, and inflammation management